Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1SC8M)

• Drug Name: Trimipramine Drug Info
• Synonyms: Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP
• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 5584
  ChEBI ID: CHEMBL644
  CAS Number: CAS 3564-75-8
  TTD Drug ID: D00HZV
  VARIDT Drug ID: DR00381
  INTEDE Drug ID: DR1649
  ACDINA Drug ID: D00708

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.46	0.00e+0	19/20 (95%)	DHCR7;SQLE;MSMO1;...
PPAR signaling pathway	2.15	0.00e+0	66/74 (89.19%)	HMGCS1;SCD;ACSL3;...
Fatty acid biosynthesis	1.96	8.83e-3	16/18 (88.89%)	ACSL3;ACSL1;ACSL4;...
Terpenoid backbone biosynthesis	1.84	1.10e-2	18/22 (81.82%)	HMGCS1;FDPS;IDI1;...
Glyoxylate and dicarboxylate metabolism	1.83	8.83e-3	23/30 (76.67%)	SHMT2;ACO2;ACAT2;...
AMPK signaling pathway	1.72	4.42e-2	106/120 (88.33%)	SCD;CD36;PFKM;...
Biosynthesis of unsaturated fatty acids	1.69	4.42e-2	21/27 (77.78%)	SCD;FADS1;FADS2;...
Primary immunodeficiency	-1.71	4.44e-2	33/38 (86.84%)	CD19;CD79A;LCK;...
Pathogenic Escherichia coli infection	-1.75	3.00e-2	152/197 (77.16%)	EZR;MAPK8;FADD;...
Drug metabolism	-1.76	2.84e-2	78/151 (51.66%)	XDH;TPMT;MGST2;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.80	1.39e-2	62/70 (88.57%)	PLCG1;MAPK11;ATP6V1D;...
NOD-like receptor signaling pathway	-1.80	1.59e-2	145/181 (80.11%)	ATG12;MAPK8;FADD;...
Fluid shear stress and atherosclerosis	-1.91	9.25e-3	123/139 (88.49%)	MAPK11;ACTB;GSTA4;...
Rheumatoid arthritis	-1.98	4.44e-3	78/93 (83.87%)	TEK;IL1B;TGFB1;...
Metabolism of xenobiotics by cytochrome P450	-2.09	0.00e+0	49/77 (63.64%)	ADH1A;ADH5;CYP2A13;...
TNF signaling pathway	-2.09	0.00e+0	103/112 (91.96%)	MAPK8;CSF1;FADD;...
NF-kappa B signaling pathway	-2.18	0.00e+0	90/104 (86.54%)	IL1R1;LCK;NFKB2;...
IL-17 signaling pathway	-2.49	0.00e+0	84/94 (89.36%)	MMP1;MAPK14;FOSB;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼